STOCK TITAN

Orchard Therapeutics plc - $ORTX STOCK NEWS

Welcome to our dedicated page for Orchard Therapeutics plc news (Ticker: $ORTX), a resource for investors and traders seeking the latest updates and insights on Orchard Therapeutics plc stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Orchard Therapeutics plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Orchard Therapeutics plc's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.3%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.77%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.62%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.75%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.75%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
conferences
Orchard Therapeutics plc

Nasdaq:ORTX

ORTX Rankings

ORTX Stock Data

380.11M
117.51M
12.21%
103.6%
0.14%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United Kingdom
108 Cannon Street

About ORTX

orchard therapeutics is dedicated to bringing transformative gene therapies to children with life-threatening orphan diseases. we work in partnership with the world’s most prestigious research centres to harness the life-giving potential of gene therapy. orchard’s leadership team and collaborators have more than a decade of experience in the development, manufacturing and commercialization of advanced therapies for orphan diseases. our mission is to provide the ideal environment and expertise to translate promising pre-clinical and early clinical results into commercially approved medicines available to patients around the world.